The government already has a real program betting aging can be solved

ARPA-H, the Advanced Research Projects Agency for Health, was established as a DARPA-style agency for medical research, willing to fund riskier, longer-horizon bets than conventional NIH grant cycles typically support. Its PROSPR program, short for Proactive Solutions for Prolonging Resilience, funds seven research teams working on a specific, hard problem in aging research: identifying early, actionable biomarkers that respond within one to three years, rather than waiting decades for disease outcomes to appear, the way conventional aging research is usually forced to. The goal stated in the program’s own materials is proving that intervening earlier can help people stay healthier for longer, using longitudinal human data rather than model organisms alone.

Over a decade before ARPA-H existed, DARPA solicited research proposals for a program called Biochronicity, aimed at identifying common timing mechanisms, described in the program materials as clock signatures, across the genome, epigenome, and proteome of both simple and complex organisms. Its stated near-term goal was improving battlefield trauma care, extending the window doctors have to treat injured soldiers by understanding how to manipulate biological timing itself. Its farther-reaching goal, named explicitly in DARPA’s own program framing, included the possibility of placing astronauts in hibernation for long spaceflight, and, in the program’s own words, hugely extended human lifespan.

This establishes that the US government has formally funded research treating human aging as a manipulable biological process, not a fixed inevitability, across two distinct programs spanning more than a decade, and that DARPA itself named radical lifespan extension as a considered outcome of its own research as early as 2011. Both programs and their stated goals are confirmed by the funding agencies’ own published program materials.

What this does not establish is that either program has produced or is close to producing a working intervention that meaningfully extends human lifespan. PROSPR’s current phase is explicitly a data-gathering effort to establish reliable biomarkers, a foundational step, not a treatment. Biochronicity’s more dramatic possibilities were named as long-term speculation within the original solicitation, not as near-term deliverables.